-
Sacituzumab govitecan, sold
under the
brand name
Trodelvy by
Gilead Sciences, is a Trop-2-directed
antibody and
topoisomerase inhibitor drug conjugate...
-
inhibitor mTNBC -PD-L1: 1st line: single-agent chemo; 3rd line:
sacituzumab govitecan mTNBC +BRCA:
patients previously treated with
chemotherapy in the neoadjuvant...
- survival. In
April 2021, the FDA
granted accelerated approval to
sacituzumab govitecan for
people with
locally advanced or
metastatic urothelial cancer (mUC)...
- "IrinotecanPathway_WP229". NK012, a
nanodevice formulation of SN-38
Sacituzumab govitecan, an antibody-drug
conjugate that uses SN-38 as the
cytotoxic drug. "CAMPTOSAR-...
-
Washkowitz S,
Sharkey RM,
Wegener WA,
Kalinsky K (February 2019). "Sacituzumab
Govitecan-hziy in
Refractory Metastatic Triple-Negative
Breast Cancer". N Engl J...
-
coronavirus SARS-CoV-2
Pegvaliese (Palynziq) for
phenylketonuria Sacituzumab govitecan (Trodelvy) for
urinary tract cancers The
graduate program at
Scripps Research...
-
target for late-stage
diseases This
antigen is the
target of
sacituzumab govitecan and
datopotamab deruxtecan (Dato-DXd), both antibody-drug conjugates....
-
Incyte Corp
metastatic cholangiocarcinoma with FGFR2
fusion Sacituzumab govitecan-hziy
Immunomedics metastatic triple-negative
breast cancer Capmatinib...
-
vedotin Prolgolimab Ramucirumab Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab...
- share),
gaining control of the
cancer treatment Trodelvy (Sacituzumab
govitecan-hziy) – a first-in-class Trop-2 antibody-drug conjugate. In December,...
